Summary of "Bad Blood: Secrets and Lies in a Silicon Valley Startup"

2 min read

Core Idea

  • Massive fraud sustained for years through charismatic leadership, prestigious board cover, aggressive legal threats, and systematic silencing of dissent—not technological innovation
  • Technology was fundamentally broken (devices didn't work, results fabricated), but deception masked failure until investigative journalism and whistleblowers exposed it
  • Combination of intimidation + compartmentalization + regulatory evasion created an environment where truth-telling was punished and lying became institutional

How the Fraud Worked

  • Abandoned failed microfluidic platform; pivoted to repurposed Edison robot that performed only immunoassays, not 200+ claimed tests
  • Finger-stick samples couldn't work at required accuracy; company used hacked Siemens machines and falsified proficiency testing results
  • Misrepresented capability to investors with fake data; provided different financial projections to different partners
  • Deployed unreliable devices in Walgreens/Safeway clinics producing wildly inaccurate patient results (vitamin D, thyroid, potassium) without validated assays

Control Mechanisms That Enabled Deception

  • Board as credibility shield: Recruited Kissinger, Mattis, Shultz, Perry—prominent names who added legitimacy but performed no oversight; offered David Boies $4.5M in stock to suppress truth
  • Culture of fear: Balwani created obsessive monitoring, routine firings, compartmentalized information; H-1B visa holders trapped by deportation threats
  • Whistleblower suppression: Anjali Laghari, Tyler Shultz, Erika Cheung, Alan Beam marginalized or fired; legal threats forced deletion of 175+ safety-concern emails
  • Aggressive litigation: Hired Boies to sue patent holder Richard Fuisz into submission despite zero evidence; used lawsuits as intimidation tool

How the Truth Emerged

  • Skeptical domain experts flag anomalies: Pathology bloggers questioned missing peer-reviewed data—credible signals journalism can trust
  • Incremental source building: Move from anonymous to on-the-record sources; cross-verify every claim across multiple independent witnesses
  • Independent verification: Carreyrou tested his own blood at both Theranos and LabCorp to confirm discrepancies; don't rely on sources alone
  • Regulatory leverage: File FOIA requests, develop relationships with agency inspectors (CMS), and trigger parallel investigations that validate reporting
  • Momentum strategy: Publish on tight deadlines before company damage control; use follow-up stories over 3 weeks to sustain pressure

Action Plan

  1. Recognize fraud signals early: Compartmentalization, aggressive NDAs, board members who can't explain technology, firing of dissenting voices
  2. Protect sources systematically: Use encrypted communication, burner phones, never disclose identities, warn about escalation in advance
  3. Document relentlessly: Keep contemporaneous notes, record conversations (legally), preserve evidence before it's destroyed
  4. Corroborate independently: Don't publish single-source claims; verify through multiple channels including your own testing where possible
  5. Appeal to institutional credibility: If leaders pressure you to suppress truth, frame suppression as damage to long-term credibility (worked with Murdoch/WSJ)
Copyright 2025, Ran DingPrivacyTerms
Summary of "Bad Blood: Secrets and Lies in a Silicon Valley Startup"